Value Investing Observatory
"Price is what you pay. Value is what you get."
Issue #33 · Weekly Stock Analysis · November 18, 2026
Welcome to this week's edition of The Buffett Lens, where we apply Warren Buffett's time-tested investment principles to identify stocks with durable competitive advantages, strong management, and sensible valuations.
Our quantitative model screens thousands of US-listed stocks against 26 key factors derived from Buffett's shareholder letters, including consistent earning power, high returns on equity with minimal debt, and favorable long-term prospects. The top-scoring stocks receive a detailed analysis written in the folksy, straightforward style that has characterized Berkshire Hathaway's communications for decades.
This week, we present 2 stocks that exemplify the principles of value investing.
Picture a sturdy old ferry boat crossing a wide river, where the captain's real skill isn't in fancy paddling but in having a hull that lets passengers board quickly and safely no matter the weather. Halozyme Therapeutics works much the same way with its enzyme technology, which helps other drug makers deliver big biologic medicines more easily through the skin and into the bloodstream.
This outfit has a wide moat, much like a castle protected from invaders, thanks to its patent-protected recombinant enzyme that stands out in the crowded healthcare field. The business shows steady revenue climbing from four hundred million to five hundred million over recent quarters, with last twelve months sales reaching one point eight billion and net income holding at five hundred million. No debt on the balance sheet keeps things simple and avoids the leverage traps that can sink returns during tough times. Management quality appears solid with strong institutional backing, even if insider ownership sits low, and the overall Buffett score of eighty two out of one hundred reflects solid alignment with buying good businesses at fair prices rather than chasing flashy growth.
Yet the record carries clear shortcomings that deserve humble notice. Return on equity has averaged negative ninety two percent over five years and sits at zero percent lately, which reminds us that even clever operators cannot overcome weak fundamental economics if the boat itself leaks. Biotech ventures often face unpredictable research costs and regulatory hurdles, so past volatility could return and test patience. The price to earnings ratio near thirty one times and enterprise value to EBITDA of twenty one times suggest the market already prices in some optimism, leaving less margin if growth slows.
Over the long haul this company could build lasting value if its enzyme platform keeps enabling successful drugs from partners, turning consistent cash flow into higher owner earnings. Buying at today's levels calls for the same steady approach one might use with a reliable but not flashy investment, waiting for intrinsic worth to compound rather than expecting quick jumps. The ticker for Halozyme Therapeutics, Inc. on eToro is $HALO.
— Buffett Bot
Trade Halozyme Therapeutics, Inc. — The ticker for Halozyme Therapeutics, Inc. on eToro is $HALO
eToro is a multi-asset investment platform. Capital at risk.
| Metric | Value | Buffett Threshold | Status |
|---|---|---|---|
| ROE (Latest) | 0.0% | >15% | FAIL |
| Debt/Equity | 0.00x | <0.5x | PASS |
| Gross Margin | 83.3% | >40% | PASS |
| Market Cap | $10.9B | >$10B | PASS |
| LTM Revenue (Last 4Q) | $1.8B | Positive, with YoY growth preferred | PASS |
| LTM Net Income (Last 4Q) | $0.5B | Positive, with YoY growth preferred | PASS |
Imagine a lively country fair where the best attractions keep drawing the same crowds year after year because everyone knows their friends will show up too. That captures the pull of Match Group's collection of dating platforms, where network effects help users find connections and the company keeps adding new brands to match different tastes.
This outfit shows real strengths that line up with sound principles of owning businesses with durable economics. The revenue climb from near zero to steady quarterly levels around $0.9 billion, paired with last-twelve-months net income of $0.7 billion, points to consistent earning power built on those network effects. A moat score of 52 reflects that protective layer, much like a castle shielded by surrounding hills rather than just a strong gate. Minimal debt at zero times equity avoids the leverage traps that can erode owner returns during tougher times, and the price-to-earnings ratio near 13 times offers a straightforward entry without stretching for growth that may not last. In my view, the focus stays on what the business itself delivers over time, not on flashy short-term moves.
Yet shortcomings deserve a clear-eyed look. The reported return on equity sitting at zero percent, both recently and on average, raises questions about how efficiently capital is truly working for owners, even if earnings appear solid on the surface. Low insider ownership at under one percent suggests management skin in the game is modest, and while institutions hold a large stake, that can sometimes bring short-term pressures rather than the patient approach these platforms need. Competition in digital matchmaking remains fierce, and user preferences can shift faster than a summer breeze, leaving even established names exposed if the fundamental boat proves less sturdy than hoped.
Over the long haul, the combination of scale in a habit-forming space and a valuation that does not demand perfection could reward those willing to hold through market swings. Patience matters here, as intrinsic value builds from steady user connections rather than quick spikes, and buying at current levels leaves room for that process to play out without overpaying. For those looking to act on this, the ticker for MTCH on eToro is $MTCH. — Buffett Bot
Trade MTCH — The ticker for MTCH on eToro is $MTCH
eToro is a multi-asset investment platform. Capital at risk.
| Metric | Value | Buffett Threshold | Status |
|---|---|---|---|
| ROE (Latest) | 0.0% | >15% | FAIL |
| Debt/Equity | 0.00x | <0.5x | PASS |
| Gross Margin | 76.8% | >40% | PASS |
| Market Cap | $9.0B | >$10B | FAIL |
| LTM Revenue (Last 4Q) | $3.5B | Positive, with YoY growth preferred | PASS |
| LTM Net Income (Last 4Q) | $0.7B | Positive, with YoY growth preferred | PASS |
The following stocks from previous issues have fallen below our Buffett thresholds. We believe in accountability - when our picks deteriorate, you should know.
Recommended in Issue #4 (2026-03-25) with score 80.1
Current score: 73.0 (-7.1 points)
ROE: 24.2% | Debt/Equity: 1.00x | Gross Margin: 38.4%
Consider reviewing your position.
Recommended in Issue #3 (2026-03-18) with score 77.6
Current score: 73.0 (-4.6 points)
ROE: 24.2% | Debt/Equity: 1.00x | Gross Margin: 38.4%
Consider reviewing your position.
Recommended in Issue #16 (2026-07-22) with score 64.5
Current score: 70.0 (+5.5 points)
ROE: 15.2% | Debt/Equity: 0.92x | Gross Margin: 21.6%
Consider reviewing your position.
Recommended in Issue #11 (2026-06-10) with score 67.0
Current score: 73.0 (+6.0 points)
ROE: 9.8% | Debt/Equity: 0.29x | Gross Margin: 39.3%
Consider reviewing your position.
Recommended in Issue #19 (2026-08-12) with score 59.0
Current score: 65.0 (+6.0 points)
ROE: 30.4% | Debt/Equity: 1.24x | Gross Margin: 29.4%
Consider reviewing your position.
This newsletter is for educational and informational purposes only and should not be construed as investment advice. The analyses presented are based on publicly available information and quantitative models. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Subscribe to The Buffett Lens and get each new issue delivered to your inbox.
Already a member? Visit robomacro.com to log in and manage subscriptions, or use Forgot Password to set a password.